Last reviewed · How we verify
NCT07507513
The Purpose of This Study is to Evaluate the Efficacy and Safety of 627 in the Treatment of UC
Phase 2 trial testing 627 in Ulcerative Colitis (UC) in 288 participants. Not yet recruiting.
28 February 2029
Quick facts
| Lead sponsor | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 288 |
| Start date | 31 March 2026 |
| Primary completion | 28 February 2029 |
| Estimated completion | 30 December 2029 |
| Sites | 1 location across China |
Drugs / interventions tested
- 627
- Placebo
Conditions studied
- Ulcerative Colitis (UC) — all drugs for Ulcerative Colitis (UC) →
Sponsor
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Ulcerative Colitis (UC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy and safety of 627 in patients with UC.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07507513
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 627
Trials testing the same drug.
- NCT07065136 — Evaluation of 627 in Healthy Adult Subjects · Phase 1 · not yet recruiting
Other recruiting trials for Ulcerative Colitis (UC)
Currently open trials in the same condition.
- NCT07335055 — A Study for HSK47388 in Participants With Ulcerative Colitis · Phase 2 · recruiting
- NCT07271069 — Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis · recruiting
- NCT07245394 — Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) · recruiting
- NCT07237516 — Zymfentra (Infliximab-dyyb) REal World Cohort STudy · recruiting
- NCT07350577 — Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants · Phase 1 · recruiting
Other Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. trials
Trials by the same sponsor.
- NCT07349329 — A Study to Evaluate the Efficacy and Safty of 608 in Patients With Non- Radiographic Axial Spondyloarthritis (Nr-axSpA) · Phase 3 · not yet recruiting
- NCT07261644 — A Study to Evaluate the Efficacy and Safety of 608 in Adult Subjects With Active Ankylosing Spondylitis(AS) · Phase 3 · recruiting
- NCT07185269 — The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE · Phase 1, PHASE2 · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT07065136 — Evaluation of 627 in Healthy Adult Subjects · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07507513 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
- Last refreshed: 2 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07507513.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing